Strength-based Treatment Approach for Adults With ADHD

May 16, 2023 updated by: Rebecca Champ, University of Huddersfield

Could a Strength- Based Treatment Improve Self-management in Adults With Attention Deficit Hyperactivity Disorder

The aim of the research is to develop a treatment program with positive self-awareness and self-determination outcomes for adults with Attention Deficit Hyperactivity Disorder (ADHD). Current treatments are based in a characterisation of ADHD oriented on deficits impairing everyday functioning, with primary goals of symptom control and reduction. However, treatment approaches are not standardised and only evidence short-term effectiveness. This project proposes an alternative approach to understanding ADHD behaviours, supported by Self Determination Theory (SDT). Research shows SDT based treatment approaches can support engagement of intrinsic motivation and longterm integration of behavioural change. ADHD research shows individuals are impaired in some contexts but not in others and can manage well, indicating potential for ADHD neurodiverse "strengths" which could be developed and supported. Recent psychology research recommends cultivating positive psychological factors and emotions to improve mental health and wellbeing. Adults aged 18+ with a confirmed ADHD diagnosis will be invited to participate in two projects: Intensive online interviews of 1 hour will be conducted to identify, explore, and construct a theory about the factors, or "natural strengths" in lived experience of ADHD that help individuals to overcome everyday impairments. These factors will be incorporated into a pilot feasibility study of an SDT based 12-week treatment programme focusing on understanding the lived experience of ADHD and building on these strengths. The treatment will be designed for individual participants and delivered online. This study will have two sets of participants: one group will go directly to treatment, the other will go on a 12-week waiting list to create a comparison group. The second group will then be offered the 12-week treatment. Measures of experience of the participants will be looking for the feasibility, acceptability and efficacy of this treatment, as well as indicators of symptom improvement, and changes in self-awareness and self-regulation skills.

Study Overview

Status

Completed

Detailed Description

ADHD symptoms negatively affect daily functioning both at work and at home, and have long-term impact in academic, occupational, social and emotional areas of functioning. Effective, long-term treatment outcomes benefit both the individual with ADHD and society as undiagnosed and untreated adults with ADHD may become an economic burden due to increased health care costs and decreased productivity at work. Russell Barkley postulated the first unifying theory of ADHD which places a core deficit of behavioural inhibition at the source of ADHD behaviours. Barkley's model is built upon observation of perceived chronic difficulties in behaviour, measured as "excessive or inappropriate for their age or development level.". Since the publication of this model, several theoretical models were proposed which attribute alternative cognitive sources for the development of ADHD symptoms, but Barkley's model forms the foundation for primary treatment recommendations. A recent review of the theories of ADHD recommended that more testable hypotheses need to be produced. While a variety of different interventions are available and the benefit of other forms of support is acknowledged (e.g. psychotherapy or coaching), the National Institute for Health and Care Excellence (NICE) only recommends interventions that match a similar protocol to medications: Randomised Controlled Trials (RCTs), which are primarily based in Cognitive Behavioural Therapy (CBT). It is therefore hypothesised that much of current research for the characterisation of ADHD is based on a cognitive behavioural paradigm that is deficit-focused with primary treatment outcomes of symptom reduction and control of maladaptive behaviours. Research in psychology suggests that a deficit-focus may not be the best approach to improving mental health, and it may be necessary to develop positive psychological factors and emotions that cultivate health and wellbeing. In ADHD, research suggests that this includes cognitive dynamism, creativity, and resilience, among others. There is a paucity of research in this area.

This project proposes an alternative approach to understanding and working with ADHD behaviours, supported by Self Determination Theory (SDT). SDT is an empirical, organismic dialectical approach to human motivation and personality, originating in Positive Psychology. SDT guided research focuses on conditions that enhance intrinsic motivation, self-regulation, and wellbeing. The positive approach to active energisation and intention of behaviour in SDT is closely aligned to evidence of positive engagement in ADHD (e.g. via interest), therefore viewing ADHD behaviours from an SDT perspective allows for a different understanding of the action and intention of behaviour. An SDT based approach combined with psychotherapeutic principles for integration of a positive concept of self provides tools which are potentially effective for long term treatment.

One of the challenges to designing effective treatment is the variability of impairment experienced by individuals with ADHD. Impairments are viewed as "clusters" of chronic difficulty for everyone with an ADHD diagnosis, however individual profiles can differ significantly. This implies there are situations or contexts where individuals with ADHD can function successfully. Two phases of this project have been developed to support this hypothesis. The aim of Phase 2 is to generate a theory, grounded in data, that explains a) why and how individuals with ADHD experience variable impairment; b) the impact of variable impairment for those with ADHD; and c) processes and strategies used by those with ADHD to resolve their main concerns regarding the impact and consequences of the variable impairment of ADHD. The purpose is to identify universal selective strengths that support individuals with ADHD to manage the variability of their impairment. In support of these alternative theories and approaches, Phase 3 of this project aims to examine the participant acceptability, feasibility, and efficacy of a novel strength - based programme of therapeutic self-development, psychoeducation and skills training for adults with a diagnosis of ADHD. This programme will use a multi-modal psychotherapeutic approach and educational methodology to assist participants in understanding ADHD and develop self-management skills.

While ADHD is primarily viewed as a neurobiological disorder with no cure, the possibility that ADHD may confer advantages to the individual is widely debated. Research on phenomena concerning the experience of ADHD has theoretical implications, and grounded theory is presented as a research methodology that is ideal for an area where not much research or theorising has been done before. There are currently several methodological approaches to grounded theory, and for this project it was deemed most appropriate to use a Constructivist approach. This approach introduces a pragmatic epistemological perspective on the researcher by recognising the subjectivity and researcher involvement in construction and interpretation of data in theory construction. This was thought to be an important element to monitor during the research process due to the researcher's own personal experience of ADHD.

In keeping with the focus on selecting cases which may provide new insights for developing theory, this project will aim to approach three different groups for participation: NHS patients from the Adult ADHD Clinic at the Southwest Yorkshire Partnership NHS Foundation Trust; university students at the University of Huddersfield and the University of Cambridge; and ADHD Support Groups for adults with ADHD. Analysis of individual case studies was considered, however as current perspectives of positive psychological factors in ADHD are identified as "individual strengths", it was thought a case comparison on interviews might identify the phenomenon in a more universal way.

The Phase 2 grounded theory research aims to reach saturation following analysis of 5-10 participant interviews. However, due to the nature of grounded theory, this can only be finalised as part of the process. It is possible more participants will

Unlike other qualitative methods, grounded theory approaches recommend that the inquiry shapes the data collection. This process of finding and generating data that is "rich", or detailed, focused, and full, provides solid material for substantive analysis. Therefore, this project will identify some areas to begin initial data collection, while remaining open to emerging potential data examples. These areas are intensive interviews, videos, and memos or field notes by the researcher.

Study Design - Pilot Study This is a wait list control study design with pre-, within, and post-treatment measures. A rolling entry of participants will be conducted, where once individuals have been screened their entry into the study will begin. A maximum of 30 adults aged 18+ with a confirmed diagnosis of ADHD will be allocated using block randomisation to the SDT theory-based model or wait list over a 12-week period. Following the 12-week wait, the wait list group will also be enrolled in the SDT theory-based model. This ensures all participants receive the opportunity to experience the treatment.

Participants will be recruited from NHS patients at the Adult ADHD Clinic at the Southwest Yorkshire Partnership NHS Foundation Trust only.Phase 3 is a pilot feasibility study, and the aim is to recruit 15 participants per arm for the two arm pilot study.

Acceptability, feasibility, and efficacy of the intervention will be measured by attendance and completion of evaluation forms at the end of each session. A follow up interview a week post-treatment will provide an opportunity for feedback and evaluation by post-treatment measures. Due to Covid-19 restrictions for research that requires in-person contact, consideration for the safety of participants and institution and NHS staff was incorporated into this study design. All interviews, screening, and treatment sessions will be conducted online, on an NHS approved video platform.

To test for treatment effects within the two groups, the psychometric data before and after therapy will be analysed statistically using a paired samples t-test, or dependant t-test. To test for treatment effects within the two groups, the psychometric data before and after therapy will be analysed statistically using the non-parametric paired-Wilcoxon test. Cohen's D will be calculated as a measure of effect size. To reduce bias, an intention to treat analysis will be used but it is recognised that challenges may occur due to missing data; based on withdrawal, loss to follow up, or non-response of assessment questionnaires and the degree of this this will be considered at the time of analysis. Therefore, the study will be reviewed using the revised Cochrane risk-of-bias tool for randomised trials (RoB 2). All analysis will be conducted with SPSS version 26.

The ethical process for this project is being reviewed by the University of Huddersfield School of Human and Health Sciences - School Research Ethics and Integrity Committee (SREIC) and will be reviewed by a relevant NHS ethics committee. Governance approvals will be obtained from university and NHS Trust sites. All sessions with Participants will be held in adherence with the Ethical Framework for Good Practice set by the UK Council for Psychotherapy (UKCP).

A British Association for Counselling and Psychotherapy (BACP) accredited psychotherapy supervisor will be engaged for two hours per month or one hour for every six patient sessions for the duration of the project to measure progress and review case work with participants if needed.

Participants will receive an invitation to an initial interview to discuss participation in the study. An information sheet detailing the purpose, activities, outcomes, and results of Phase 2 will be provided, including the researcher contact details (name, phone number, email address). Participants will be encouraged to read the information sheet again and ask questions on the assessment day prior to signing the consent form. The voluntary nature of participation and the ability to withdraw an individual's consent at any time will be emphasised during the study.

For the Phase 2 intensive interviews, all participants will be entered into a draw for a £50 Amazon voucher. This was suggested by the lived experience group as contribution to research for ADHD was not considered enough of a benefit alone.

For participants in the Phase 3 pilot study, they will receive 11 weekly sessions of individually focused therapeutic coaching support which is not currently accessible within the service. It is possible that a waitlist control design study might be an incentive for participants to join, as all participants in the study will eventually receive the intervention. However, we considered it unethical to offer a place in the study without the option to receive the intervention. Participants will be given a minimum of 24 hours and up to three days to consider participation in the study, and the researcher will be available to answer any questions they have.

A critical element of this research project is the exploration and representation of the lived experience of adults with ADHD, and the applicability, efficacy, and accessibility of the results. Therefore, this project has involved a patient participation group in pre-study preparation before recruitment. A small group of 5-6 adults with ADHD who expressed strong interest in the research have reviewed and refined recruitment materials for Phase 2 and Phase 3, including the recruitment flyers, patient information sheets, consent forms and interview guide.

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • West Yorkshire
      • Huddersfield, West Yorkshire, United Kingdom, HD1 3DH
        • University of Huddersfield
      • Wakefield, West Yorkshire, United Kingdom, WF1 5PN
        • Manygates Adult ADHD Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 78 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Confirmed diagnosis of ADHD
  • Age 18 or older
  • Access to computer or smartphone with an internet connection

Exclusion Criteria:

  • Co-morbid diagnosis (e.g. Autism, Bi-polar, Learning Disabilities, Traumatic Brain Injury, Psychosis or Tourette's)
  • Substance abuse disorders
  • Other mental health disorders (e.g. PTSD, Oppositional Defiant Disorder
  • Personality Disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
SDT theory-based psychotherapeutic treatment model
12 week individual therapeutic coaching intervention
No Intervention: Control
Wait List

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Weiss Functional Impairment Rating Scale -WFIRS
Time Frame: Baseline and immediately after intervention
Measures change in severity of ADHD symptoms. Lilkert scale where the total score can be reviewed, or a mean score from each relevant domain. Higher scores mean worse outcome.
Baseline and immediately after intervention
Patient Heath Questionniare (PHQ)- 9
Time Frame: Baseline and immediately after intervention
Major Depressive Disorder section of larger PHQ measuring change in severity of Depression symptoms. Minimim score 0, maximum score 27, higher scores mean worse outcome.
Baseline and immediately after intervention
General Anxiety Disorder (GAD) 7
Time Frame: Baseline and immediately after intervention
Measures change in severity of Anxiety symptoms. Scale score ranges from 0 to 21 with cut points of 5, 10, and 15 that might be interpreted as representing mild, moderate, and severe levels of anxiety. Higher scores mean worse outcome.
Baseline and immediately after intervention
Harter's Self Perception Profile
Time Frame: Baseline and immediately after intervention
Measures changes in self awareness. Each item has minimum score of 1, maximum score of 4. Mean scores are calculated for each of 12 sub-domains. Higher scores mean better outcome.
Baseline and immediately after intervention
Index of Autonomous Functioning -IAF
Time Frame: Baseline and immediately after intervention
Measures changes in feeling self-determined. Each item scores minimum 1, maximum 5 and total is calculated by averaging scores from 15 items. Higher scores mean better outcome.
Baseline and immediately after intervention
Perceived Choice and Awareness of Self Scale -PCASS
Time Frame: Baseline and immediately after intervention
Measures changes in feeling self-determined. Likert 10-item scale, with two 5-item subscales with minimum of 1 and maximum of 5 on each item. Total is calculated by averaging scores in each subscale, with higher scores meaning a better outcome.
Baseline and immediately after intervention
Personal Questionnaire - PQ
Time Frame: During the intervention
Measure change in participant selected specific psychological difficulties. 10 problems are measured weekly with score of minimum 1, maximum 7. Total is calculated by averaging scores in each subscale, with higher scores meaning a better outcome.
During the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Barry Tolchard, University of Huddersfield

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 6, 2021

Primary Completion (Actual)

April 17, 2023

Study Completion (Actual)

April 17, 2023

Study Registration Dates

First Submitted

March 29, 2021

First Submitted That Met QC Criteria

April 1, 2021

First Posted (Actual)

April 6, 2021

Study Record Updates

Last Update Posted (Actual)

May 17, 2023

Last Update Submitted That Met QC Criteria

May 16, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

To protect identity of individual participants, all personally identifiable data (PID) will be anonymised and will not be released. All participant case records will be held in accordance with the Data Protection Act. Records will be kept both in electronic and hard copy form. The participants' home addresses and telephone numbers will be kept on a secure database and spreadsheet on NHS/University computers in compliance to the Data Protection Act. Data held in the NVivo database will be anonymised and only accessible by password protected researcher login. All manual records will be kept in a locked cabinet accessible by the researcher only.

In accordance with the Data Protection Act personal data will not be retained for longer than is necessary. The University of Huddersfield recommends that data is stored for 10 years to aid transparency and integrity of research. Long term storage of data will be accessible by the researcher only.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Attention Deficit Hyperactivity Disorder

Clinical Trials on ADDapt Ability Framework

3
Subscribe